Multicentre Clinical Study of Ultra-Fast-Track Anaesthesia for Minimally Invasive Heart Valve Surgery

NCT ID: NCT06541483

Last Updated: 2024-08-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

1200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-12-31

Study Completion Date

2028-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to evaluate the clinical effects of ultra-fast-track anesthesia (UFTA) for minimally invasive cardiac surgery (MICS) in adults. It will also learn about the safety and feasibility of Ultra-Fast-Track cardiac surgery(UFTCA).The main questions it aims to answer are:Does UFTCA promote rapid postoperative recovery, reduce postoperative complications and perioperative mortality, and improve the quality of mid- and long-term survival.And does it improve patient satisfaction and reduce healthcare costs.

Participants will receive homogenized perioperative management in the cardiac ward, extracorporeal circulation, and postoperative ICU, except for anesthesia extubation time.Furthermore,Participants need complete quality of life scales at 30 days, 90 days, six months, and one year after surgery, separately.

Participants in this study are adults who required elective minimally invasive heart valve surgery under extracorporeal circulation.This study will be able to promote rapid recovery while reducing the associated costs and the financial burden on participants.Retrospective big data analysis of perioperative clinical characteristics of patients undergoing minimally invasive heart valve surgery to establish a risk warning model and develop a perioperative management program. The investigators then conducts a randomized group trial comparing the similarities and differences between conventional general anesthesia(CGA) and ultra-fast-track cardiac anesthesia(URTCA) to demonstrate the effectiveness and safety of UFTA in MICS.Finally, building expert consensus.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study was divided into two parts:The first part is retrospective data collection and organization, screening risk factors to establish an early warning model to improve the perioperative management program, and the other part is conducted using a randomized controlled trial to evaluate the effectiveness, safety and benefit of the perioperative management program of ultra-fast-track anesthesia(UFTA) for minimally invasive heart valve surgery. The specific program is as follows:

Part I

1. Establishment of an information collection platform Log in to the platform for electronic data entry and retain the paper version of the CaseReportForm(CRF)
2. Retrospective data collection Relying on the National Head Medical Center for Cardiac Surgery, 5000 perioperative case data of minimally invasive heart valve surgery patients were counted to obtain the perioperative clinical characteristics of Chinese adult minimally invasive heart valve surgery patients.
3. Screening for risk factors Statistical analysis of risk factors affecting perioperative ultra-fast-track anesthesia delivery and postoperative complications
4. Establishment of early warning model Combining age stratification, surgical mode stratification and general characteristics, establish an early warning model to improve the perioperative management protocol of ultra-fast channel anesthesia for minimally invasive heart valve surgery.

Part II Recruitment of participants for a prospective randomized controlled trial

1. Participants Patients undergoing elective minimally invasive adult heart valve surgery will be selected after completion of history taking, physical examination, preoperative laboratory and ancillary investigations, preoperative health and quality of life questionnaires, and frailty assessment of their physical condition, and will be confirmed to be free of any one of the "Exclusion Criteria" and to meet any one or more of the "Inclusion Criteria". Those who fulfill any one of the "Exclusion Criteria" and more than one of the "Inclusion Criteria" will be given a screening number. After completing the basic information and preoperative medications, the participant signed the informed consent form. If either the participant or the family member does not agree to participate in the study, the participant will only be given a screening number and the study will end here.
2. Randomized grouping Participants who were included to meet the criteria were randomly divided into the ultra-fast-track anesthesia group (UFTCA) and the conventional general anesthesia group (CGA), and the homogenized perioperative management of the extracardiac ward, extracorporeal circulation, and postoperative ICU was implemented, except for anesthesia resuscitation methods.
3. Anesthesia management 3.1 Preoperative Preoperative education, nutritional support, fasting and abstinence from food and drink, prophylactic multimodal analgesia (preoperative oral pregabalin 150 mg and acetaminophen 1000 mg) 3.2 Intraoperative Anesthesia mode: tracheal intubation general anesthesia plus nerve block anesthesia Induction of anesthesia: intravenous slow push etomidate fat milk injection 0.15 mg/kg, propofol injection 0.5\~1.0 mg/kg, sufentanil citrate injection 0.4\~0.5 mg/kg, rocuronium bromide 0.6\~0.8 mg/kg, to be the patient's consciousness disappeared, to be the mask pressurized denitrification of oxygen for 3\~5 minutes, muscle relaxation after the complete effect of the laryngoscopy under the direct visualization The patient was intubated, fixed, and mechanically ventilated, and the respiratory parameters were set as follows: Fraction of inspiratory oxygen concentration (FiO2): 50\~80%, tidal volume (VT): 6\~8 ml/kg, respiratory rate (RR): 10\~12 times/min, Inhalation-exhalation ratio (I:E): 1:2, Maintain End-tidal CarbonDioxidePartialPressure (PetCO2) at 35\~45 mmHg.

Anesthesia maintenance: Propofol injection 150\~250 μg/(kg·min) and remifentanil 0.2\~0.4 μg/(kg·min) were continuously pumped through the central venous catheter, and intraoperative EEG Bispectral Index (BIS) values were maintained between 40\~60.

According to the hemodynamic indexes, respiratory parameters and the needs of surgical operation, intravenous sufentanil was injected in divided doses of 0.1\~0.2 μg/kg, and the total amount of intraoperative sufentanil was controlled to be 1.0\~1.5 μg/kg.

Additional rocuronium bromide 0.1\~0.2 mg/kg was added at the time of aortic blockade and opening, respectively.

Intraoperative multimodal analgesia: (Pectoral nerves I(Pecs I), Pectoral nerves II(Pecs II), anterior serratus plane block(SPB)) anesthetic resuscitation: Evaluate to confirm whether the patient can be included in ultra-fast-track anesthesia.

After the aorta was opened, the anesthesiologist, by observing the surgical procedure and communicating with the surgeon as well as the sonographer in a timely manner, confirmed that the surgery was successful, the heart was restarting normally, the extracorporeal circulation was withdrawn smoothly, there was no active hemorrhage in the surgical field, hemostasis was complete, oxygenation was functioning well, and the patient's finger pulse oximetry saturation was ≥98% under conditions of inhaled pure oxygen.

UFTCA:The amount of propofol maintenance was dynamically adjusted according to the degree of stimulation at the beginning of chest closure, and all intravenous anesthesia maintenance drugs were discontinued at the beginning of chest closure. When the patient is under deep anesthesia, clear the patient's airway secretions and other foreign objects in advance; without interfering with the surgeon's operation, give bilateral lung bulging, and according to the trend of the BIS value and the patient's somatic reaction or not, give a single intravenous injection of propofol of 20\~30mg as appropriate to maintain the patient's sedation until the end of the operation, and then remove the airway catheter when the patient is fully awake on the operating table. If necessary, an appropriate amount of neostigmine methylsulfate 1mg and atropine sulfate injection 0.5mg can be used intravenously to antagonize the muscle relaxant.

CGA:Propofol injection 150\~250 μg/(kg·min) and remifentanil 0.2\~0.4 ug/(kg·min) were continuously pumped, and the patients were transferred to the ICU with tubes, and the ICU doctors decided the timing of stopping sedation and extubation.

3.3 Postoperative multimodal analgesia Immediately after surgery, an intravenous analgesic pump was connected (sufentanil 200 μg and palonosetron 0.25 mg saline configured to a total of 200 mL)
4. Surgery Valve surgery encompasses aortic valve / mitral valve / tricuspid valve disease, performing single / double / triple valves, using minimally invasive procedures.This can be done through a small upper sternal incision, a small right anterior chest incision or a small transaxillary incision.
5. Extracorporeal circulation management The pre-filled fluid for extracorporeal circulation was 500\~750 ml of crystalloid, 150 ml of 20% mannitol, 100 ml of 20% albumin, and 150 ml of sodium bicarbonate.

Heparinization was performed at 3\~4 mg/kg, and extracorporeal circulation was started after activated clotting time(ACT)\>480s. The pacing fluid and dosage was 30 ml/kg, and the total amount did not exceed 2000 ml.

During extracorporeal circulation, the mean arterial pressure was maintained at 50\~80 mmHg, and the perfusion flow rate was 2.2\~2.4 L/m\^2.
6. Postoperative monitoring The Visual Analogue Score (VAS) was used for pain assessment after tracheal tube removal. VAS pain score by the nurse every 4 hours, if VAS ≥ 3, then press the analgesic pump once additional sufentanil 3 \~ 5 μg, 3 minutes later to assess again, if the patient VAS ≥ 3, then press the analgesic pump again additional sufentanil 3 \~ 5 μg; if sufentanil reached the analgesic pump set the limit of the amount of VAS ≥ 3 or produce serious nausea and vomiting and other side effects, then the intravenous oxycodone 10mg / time for Remedial analgesia.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Valve Diseases Enhanced Recovery After Surgery

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ultra-Fast-Track Cardiac Anesthesia(UFTCA)

The researchers implemented an ultra-fast-track anesthesia protocol, and the tracheal tube was removed immediately or within 1 hour of awakening at the end of the operation.

Group Type EXPERIMENTAL

Ultra-Fast-Track Cardiac Anesthesia(UFTCA)

Intervention Type PROCEDURE

(UFTCA)The researcher removed the endotracheal tube either immediately or within 1 hour of the end of the procedure.

conventional general anesthesia (CGA)

The researcher implemented a conventional anesthesia protocol, and participants were not extubated at the end of the procedure and were admitted to the ICU under anesthesia with an endotracheal tube.

Group Type OTHER

conventional general anesthesia (CGA)

Intervention Type PROCEDURE

(CGA)The researcher not extubated at the end of the operation and were admitted to the ICU under anesthesia with an endotracheal tube.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ultra-Fast-Track Cardiac Anesthesia(UFTCA)

(UFTCA)The researcher removed the endotracheal tube either immediately or within 1 hour of the end of the procedure.

Intervention Type PROCEDURE

conventional general anesthesia (CGA)

(CGA)The researcher not extubated at the end of the operation and were admitted to the ICU under anesthesia with an endotracheal tube.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥18 and ≤80 years
* American Society of Anaesthesiologists (ASA) class I-III
* New York Heart Association (NYHA) cardiac class III or below
* Preoperative inspired air pulse oximetry (SpO2) ≥95%
* Ejection fraction (EF) ≥ 40%
* No contraindications to nerve blocks

Exclusion Criteria

* Patient's refusal to participate
* Severe communication disorders
* Severe disorders of coagulation with spontaneous bleeding tendency
* Long-term application of opioid analgesics
* Pulmonary hypertension (mean pulmonary artery pressure ≥55 mmHg)
* People who need artificial ventilation
* Allergy to dexmedetomidine and ropivacaine
* Complex aortic root surgery such as root widening
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Beijing Anzhen Hospital

OTHER

Sponsor Role collaborator

Fudan University

OTHER

Sponsor Role collaborator

Wuhan Asia Heart Hospital

OTHER

Sponsor Role collaborator

Tianjin Chest Hospital

OTHER

Sponsor Role collaborator

Chinese PLA General Hospital

OTHER

Sponsor Role collaborator

First Affiliated Hospital Xi'an Jiaotong University

OTHER

Sponsor Role collaborator

Xiangya Hospital of Central South University

OTHER

Sponsor Role collaborator

The Fourth Affiliated Hospital of Zhejiang University School of Medicine

OTHER

Sponsor Role collaborator

Guangdong Provincial People's Hospital

OTHER

Sponsor Role collaborator

Zhejiang Provincial People's Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mei J Yan, QC

Role: STUDY_CHAIR

Zhejiang Provincial People's Hospital

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Mei J Yan, QC

Role: CONTACT

+863313957116714

Han W Wei, secretary

Role: CONTACT

+863317816112656

References

Explore related publications, articles, or registry entries linked to this study.

Krzych L, Kucewicz-Czech E. It is time for enhanced recovery after surgery in cardiac surgery. Kardiol Pol. 2017;75(5):415-420. doi: 10.5603/KP.a2017.0014. Epub 2017 Feb 2. No abstract available.

Reference Type BACKGROUND
PMID: 28150277 (View on PubMed)

Kehlet H. Multimodal approach to control postoperative pathophysiology and rehabilitation. Br J Anaesth. 1997 May;78(5):606-17. doi: 10.1093/bja/78.5.606.

Reference Type BACKGROUND
PMID: 9175983 (View on PubMed)

Coleman SR, Chen M, Patel S, Yan H, Kaye AD, Zebrower M, Gayle JA, Liu H, Urman RD. Enhanced Recovery Pathways for Cardiac Surgery. Curr Pain Headache Rep. 2019 Mar 14;23(4):28. doi: 10.1007/s11916-019-0764-2.

Reference Type BACKGROUND
PMID: 30868281 (View on PubMed)

Zaouter C, Imbault J, Labrousse L, Abdelmoumen Y, Coiffic A, Colonna G, Jansens JL, Ouattara A. Association of Robotic Totally Endoscopic Coronary Artery Bypass Graft Surgery Associated With a Preliminary Cardiac Enhanced Recovery After Surgery Program: A Retrospective Analysis. J Cardiothorac Vasc Anesth. 2015 Dec;29(6):1489-97. doi: 10.1053/j.jvca.2015.03.003. Epub 2015 Mar 5.

Reference Type BACKGROUND
PMID: 26119408 (View on PubMed)

Fleming IO, Garratt C, Guha R, Desai J, Chaubey S, Wang Y, Leonard S, Kunst G. Aggregation of Marginal Gains in Cardiac Surgery: Feasibility of a Perioperative Care Bundle for Enhanced Recovery in Cardiac Surgical Patients. J Cardiothorac Vasc Anesth. 2016 Jun;30(3):665-70. doi: 10.1053/j.jvca.2016.01.017. Epub 2016 Jan 16.

Reference Type BACKGROUND
PMID: 27321791 (View on PubMed)

Williams JB, McConnell G, Allender JE, Woltz P, Kane K, Smith PK, Engelman DT, Bradford WT. One-year results from the first US-based enhanced recovery after cardiac surgery (ERAS Cardiac) program. J Thorac Cardiovasc Surg. 2019 May;157(5):1881-1888. doi: 10.1016/j.jtcvs.2018.10.164. Epub 2018 Dec 8.

Reference Type BACKGROUND
PMID: 30665758 (View on PubMed)

Engelman DT, Ben Ali W, Williams JB, Perrault LP, Reddy VS, Arora RC, Roselli EE, Khoynezhad A, Gerdisch M, Levy JH, Lobdell K, Fletcher N, Kirsch M, Nelson G, Engelman RM, Gregory AJ, Boyle EM. Guidelines for Perioperative Care in Cardiac Surgery: Enhanced Recovery After Surgery Society Recommendations. JAMA Surg. 2019 Aug 1;154(8):755-766. doi: 10.1001/jamasurg.2019.1153.

Reference Type BACKGROUND
PMID: 31054241 (View on PubMed)

Pokhrel S, Gregory A, Mellor A. Perioperative care in cardiac surgery. BJA Educ. 2021 Oct;21(10):396-402. doi: 10.1016/j.bjae.2021.05.008. Epub 2021 Jul 13. No abstract available.

Reference Type BACKGROUND
PMID: 34567795 (View on PubMed)

Cohen B, Turan A. Enhanced recovery after cardiac surgery - Is evidence still necessary? J Clin Anesth. 2019 May;54:171-172. doi: 10.1016/j.jclinane.2018.12.049. Epub 2018 Dec 29. No abstract available.

Reference Type BACKGROUND
PMID: 30599274 (View on PubMed)

Noss C, Prusinkiewicz C, Nelson G, Patel PA, Augoustides JG, Gregory AJ. Enhanced Recovery for Cardiac Surgery. J Cardiothorac Vasc Anesth. 2018 Dec;32(6):2760-2770. doi: 10.1053/j.jvca.2018.01.045. Epub 2018 Jan 31.

Reference Type BACKGROUND
PMID: 29503121 (View on PubMed)

Bianchi P, Constantine A, Costola G, Mele S, Shore D, Dimopoulos K, Aw TC. Ultra-Fast-Track Extubation in Adult Congenital Heart Surgery. J Am Heart Assoc. 2021 Jun;10(11):e020201. doi: 10.1161/JAHA.120.020201. Epub 2021 May 17.

Reference Type BACKGROUND
PMID: 33998289 (View on PubMed)

Zayat R, Menon AK, Goetzenich A, Schaelte G, Autschbach R, Stoppe C, Simon TP, Tewarie L, Moza A. Benefits of ultra-fast-track anesthesia in left ventricular assist device implantation: a retrospective, propensity score matched cohort study of a four-year single center experience. J Cardiothorac Surg. 2017 Feb 8;12(1):10. doi: 10.1186/s13019-017-0573-9.

Reference Type BACKGROUND
PMID: 28179009 (View on PubMed)

Xu J, Zhou G, Li Y, Li N. Benefits of ultra-fast-track anesthesia for children with congenital heart disease undergoing cardiac surgery. BMC Pediatr. 2019 Dec 11;19(1):487. doi: 10.1186/s12887-019-1832-9.

Reference Type BACKGROUND
PMID: 31829170 (View on PubMed)

Akhtar MI, Momeni M, Szekely A, Hamid M, El Tahan MR, Rex S. Multicenter International Survey on the Clinical Practice of Ultra-Fast-Track Anesthesia with On-Table Extubation in Pediatric Congenital Cardiac Surgery. J Cardiothorac Vasc Anesth. 2019 Feb;33(2):406-415. doi: 10.1053/j.jvca.2018.07.006. Epub 2018 Jul 7.

Reference Type BACKGROUND
PMID: 30115517 (View on PubMed)

Jiang S, Wang L, Teng H, Lou X, Wei H, Yan M. The Clinical Application of Ultra-Fast-Track Cardiac Anesthesia in Right-Thoracoscopic Minimally Invasive Cardiac Surgery: A Retrospective Observational Study. J Cardiothorac Vasc Anesth. 2023 May;37(5):700-706. doi: 10.1053/j.jvca.2023.01.010. Epub 2023 Jan 13.

Reference Type BACKGROUND
PMID: 36804223 (View on PubMed)

Ahmad U, Khattab MA, Schaelte G, Goetzenich A, Foldenauer AC, Moza A, Tewarie L, Stoppe C, Autschbach R, Schnoering H, Zayat R. Combining Minimally Invasive Surgery With Ultra-Fast-Track Anesthesia in HeartMate 3 Patients: A Pilot Study. Circ Heart Fail. 2022 May;15(5):e008358. doi: 10.1161/CIRCHEARTFAILURE.121.008358. Epub 2022 Mar 7.

Reference Type BACKGROUND
PMID: 35249368 (View on PubMed)

Feng J, Wang H, Peng L, Xu H, Song X. Effects of Thoracic Paravertebral Block on Postoperative Analgesia in Infants and Small Children undergoing Ultra-Fast Track Cardiac Anesthesia: A Randomized Controlled Trial. J Cardiothorac Vasc Anesth. 2023 Apr;37(4):539-546. doi: 10.1053/j.jvca.2022.12.006. Epub 2022 Dec 11.

Reference Type BACKGROUND
PMID: 36717316 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

099

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Reduction of Remifentanil-related Complications
NCT01003028 NOT_YET_RECRUITING PHASE4